Dr Monk on the Investigation of B7-H4–Directed Vedotin ADCs in Gynecologic Cancers
Bradley Monk, MD, FACS, FACOG, discusses the rationale for investigating B7-H4–directed vedotin antibody-drug conjugates and highlights how these agents may address unmet needs for patients with gynecologic cancers.
Source: onclive.com